Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, Philippe Moreau, Xavier Leleu et al.|Leukemia|2011Cited by 721
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Albert Oriol et al.|The Lancet Oncology|2019Cited by 383
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II StudyAnas Younes, Andreas Engert, Anna Sureda et al.|Journal of Clinical Oncology|2012Cited by 261
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyFederica Cavallo, Antonio Palumbo, Giuseppe Milone et al.|Leukemia|2011Cited by 63
Differential regulation of the apoptotic machinery during megakaryocyte differentiation and platelet production by inhibitor of apoptosis protein LivinIhab Abd‐Elrahman, Dina Ben‐Yehuda|Cell Death and Disease|2013Cited by 12